Monitoring tumor response to antivascular therapy using non-contrast intravoxel incoherent motion diffusion-weighted MRI

Changzheng Shi, Dexiang Liu, Zeyu Xiao, Dong Zhang, Guanfu Liu, Guanshu Liu, Hanwei Chen, Liangping Luo

Research output: Contribution to journalArticle

Abstract

Antivascular therapy is a promising approach to the treatment of non–small cell lung cancer (NSCLC), where an imaging modality capable of longitudinally monitoring treatment response could provide early prediction of the outcome. In this study, we sought to investigate the feasibility of using intravoxel incoherent motion (IVIM) diffusion MRI to quantitatively assess the efficacy of the treatments of a vascular-disrupting agent CA4P or its combination with bevacizumab on experimental NSCLC tumors. CA4P caused a strong but reversible effect on tumor vasculature; all perfusion-related parameters—D*, f, fD*, and Ktrans—initially showed a decrease of 30% to 60% at 2 hours and then fully recovered to baseline on day 2 for CA4P treatment or on days 4 to 8 for CA4P + bevacizumab treatment; the diffusion coefficient in tumors decreased initially at 2 hours and then increased from day 2 to day 8. We observed a good correlation between IVIM parameters and dynamic contrast-enhanced MRI (DCE-MRI; Ktrans). We also found that the relative change in f and fD* at 2 hours correlated well with changes in tumor volume on day 8. In conclusion, our results suggest that IVIM is a promising alternative to DCE-MRI for the assessment of the change in tumor perfusion as a result of antivascular agents and can be used to predict the efficacy of antivascular therapies without the need for contrast media injection.

Original languageEnglish (US)
Pages (from-to)3491-3501
Number of pages11
JournalCancer Research
Volume77
Issue number13
DOIs
StatePublished - Jul 1 2017

Fingerprint

Diffusion Magnetic Resonance Imaging
Neoplasms
Non-Small Cell Lung Carcinoma
Tumor Burden
Contrast Media
Blood Vessels

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Monitoring tumor response to antivascular therapy using non-contrast intravoxel incoherent motion diffusion-weighted MRI. / Shi, Changzheng; Liu, Dexiang; Xiao, Zeyu; Zhang, Dong; Liu, Guanfu; Liu, Guanshu; Chen, Hanwei; Luo, Liangping.

In: Cancer Research, Vol. 77, No. 13, 01.07.2017, p. 3491-3501.

Research output: Contribution to journalArticle

Shi, Changzheng; Liu, Dexiang; Xiao, Zeyu; Zhang, Dong; Liu, Guanfu; Liu, Guanshu; Chen, Hanwei; Luo, Liangping / Monitoring tumor response to antivascular therapy using non-contrast intravoxel incoherent motion diffusion-weighted MRI.

In: Cancer Research, Vol. 77, No. 13, 01.07.2017, p. 3491-3501.

Research output: Contribution to journalArticle

@article{f3a0a21e4b644118b908468ad6363d99,
title = "Monitoring tumor response to antivascular therapy using non-contrast intravoxel incoherent motion diffusion-weighted MRI",
abstract = "Antivascular therapy is a promising approach to the treatment of non–small cell lung cancer (NSCLC), where an imaging modality capable of longitudinally monitoring treatment response could provide early prediction of the outcome. In this study, we sought to investigate the feasibility of using intravoxel incoherent motion (IVIM) diffusion MRI to quantitatively assess the efficacy of the treatments of a vascular-disrupting agent CA4P or its combination with bevacizumab on experimental NSCLC tumors. CA4P caused a strong but reversible effect on tumor vasculature; all perfusion-related parameters—D*, f, fD*, and Ktrans—initially showed a decrease of 30% to 60% at 2 hours and then fully recovered to baseline on day 2 for CA4P treatment or on days 4 to 8 for CA4P + bevacizumab treatment; the diffusion coefficient in tumors decreased initially at 2 hours and then increased from day 2 to day 8. We observed a good correlation between IVIM parameters and dynamic contrast-enhanced MRI (DCE-MRI; Ktrans). We also found that the relative change in f and fD* at 2 hours correlated well with changes in tumor volume on day 8. In conclusion, our results suggest that IVIM is a promising alternative to DCE-MRI for the assessment of the change in tumor perfusion as a result of antivascular agents and can be used to predict the efficacy of antivascular therapies without the need for contrast media injection.",
author = "Changzheng Shi and Dexiang Liu and Zeyu Xiao and Dong Zhang and Guanfu Liu and Guanshu Liu and Hanwei Chen and Liangping Luo",
year = "2017",
month = "7",
doi = "10.1158/0008-5472.CAN-16-2499",
volume = "77",
pages = "3491--3501",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "13",

}

TY - JOUR

T1 - Monitoring tumor response to antivascular therapy using non-contrast intravoxel incoherent motion diffusion-weighted MRI

AU - Shi,Changzheng

AU - Liu,Dexiang

AU - Xiao,Zeyu

AU - Zhang,Dong

AU - Liu,Guanfu

AU - Liu,Guanshu

AU - Chen,Hanwei

AU - Luo,Liangping

PY - 2017/7/1

Y1 - 2017/7/1

N2 - Antivascular therapy is a promising approach to the treatment of non–small cell lung cancer (NSCLC), where an imaging modality capable of longitudinally monitoring treatment response could provide early prediction of the outcome. In this study, we sought to investigate the feasibility of using intravoxel incoherent motion (IVIM) diffusion MRI to quantitatively assess the efficacy of the treatments of a vascular-disrupting agent CA4P or its combination with bevacizumab on experimental NSCLC tumors. CA4P caused a strong but reversible effect on tumor vasculature; all perfusion-related parameters—D*, f, fD*, and Ktrans—initially showed a decrease of 30% to 60% at 2 hours and then fully recovered to baseline on day 2 for CA4P treatment or on days 4 to 8 for CA4P + bevacizumab treatment; the diffusion coefficient in tumors decreased initially at 2 hours and then increased from day 2 to day 8. We observed a good correlation between IVIM parameters and dynamic contrast-enhanced MRI (DCE-MRI; Ktrans). We also found that the relative change in f and fD* at 2 hours correlated well with changes in tumor volume on day 8. In conclusion, our results suggest that IVIM is a promising alternative to DCE-MRI for the assessment of the change in tumor perfusion as a result of antivascular agents and can be used to predict the efficacy of antivascular therapies without the need for contrast media injection.

AB - Antivascular therapy is a promising approach to the treatment of non–small cell lung cancer (NSCLC), where an imaging modality capable of longitudinally monitoring treatment response could provide early prediction of the outcome. In this study, we sought to investigate the feasibility of using intravoxel incoherent motion (IVIM) diffusion MRI to quantitatively assess the efficacy of the treatments of a vascular-disrupting agent CA4P or its combination with bevacizumab on experimental NSCLC tumors. CA4P caused a strong but reversible effect on tumor vasculature; all perfusion-related parameters—D*, f, fD*, and Ktrans—initially showed a decrease of 30% to 60% at 2 hours and then fully recovered to baseline on day 2 for CA4P treatment or on days 4 to 8 for CA4P + bevacizumab treatment; the diffusion coefficient in tumors decreased initially at 2 hours and then increased from day 2 to day 8. We observed a good correlation between IVIM parameters and dynamic contrast-enhanced MRI (DCE-MRI; Ktrans). We also found that the relative change in f and fD* at 2 hours correlated well with changes in tumor volume on day 8. In conclusion, our results suggest that IVIM is a promising alternative to DCE-MRI for the assessment of the change in tumor perfusion as a result of antivascular agents and can be used to predict the efficacy of antivascular therapies without the need for contrast media injection.

UR - http://www.scopus.com/inward/record.url?scp=85023768316&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85023768316&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-16-2499

DO - 10.1158/0008-5472.CAN-16-2499

M3 - Article

VL - 77

SP - 3491

EP - 3501

JO - Cancer Research

T2 - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 13

ER -